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D-PEPTIDES DEVELOPED TO BE THERAPEUTICALLY ACTIVE AGAINST BETA-
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Objectives: To date, no treatment exists to cure Alzheimer’s disease (AD). Aggregation 
of beta-amyloid (Abeta) plays an important role in the pathology of AD. Currently, Abeta 
oligomers are thought to be the most toxic species. D3, a D-enantiomeric peptide (D-
peptide), was developed that specifically eliminates Abeta oligomers in vitro and has 
been shown to improve cognition and reduce plaque load and inflammation in transgenic 
Alzheimer’s mice. D-peptides have several advantages over L-peptides since they are 
less immunogenic and more protease-resistant. Therefore, they are thought to remain 
longer in the body providing more time to be therapeutically active. Here, we show 
pharmacokinetic studies of some derivatives of D3 in mice and estimate their plasma 
protein binding. 
Methods: Radioactively labelled peptide was administered via several administration 
routes and organs were harvested at different time points post injection. The amount of 
radioactive D-peptide in the organ homogenate was measured by liquid scintillation 
counting. Furthermore, binding to plasma proteins as well as brain membranes was 
determined, also using radioactively labelled peptide as indicator.  
Results: Results show that all D-peptides indeed reach the brain where they may exhibit 
their therapeutic activity. Furthermore, the peptides show small elimination constants 
and long half-lives of more than a day in plasma as well as a high bioavailability after 
i.p., s.c. or p.o. administration.  
Conclusions: Promising pharmacokinetic properties confirm that D-peptides may be 
very potent AD-therapeutic agents on their way to clinical studies. 
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